Last reviewed · How we verify
PPI (proton pump inhibitor)
Proton pump inhibitors block the hydrogen/potassium ATPase enzyme in gastric parietal cells, reducing gastric acid secretion.
Proton pump inhibitors block the hydrogen/potassium ATPase enzyme in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | PPI (proton pump inhibitor) |
|---|---|
| Also known as | pantoprazole, lansoprazole, dexlansoprazole, rabeprazole |
| Sponsor | University of Bologna |
| Drug class | Proton pump inhibitor |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
PPIs irreversibly inhibit the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, which is the final step in gastric acid production. This leads to sustained suppression of both basal and stimulated acid secretion across all meal times. PPIs are prodrugs that require activation in the acidic environment of the stomach to exert their effect.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Hypomagnesemia (chronic use)
- Vitamin B12 deficiency (chronic use)
Key clinical trials
- Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD (PHASE2)
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial. (NA)
- OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers (PHASE4)
- Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy (NA)
- Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction (PHASE4)
- Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor (PHASE2)
- A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PPI (proton pump inhibitor) CI brief — competitive landscape report
- PPI (proton pump inhibitor) updates RSS · CI watch RSS
- University of Bologna portfolio CI